公开(公告)号：US20080089837A1

公开(公告)日：2008-04-17

申请号：US11833473

申请日：2007-08-03

申请人： Naomi LAING ,  Jaspal Kang ,  Ian Foltz ,  Gadi Gazit-Bornstein ,  Xiao-Dang Yang ,  David Blakey ,  Sue Cartlidge

发明人： Naomi LAING ,  Jaspal Kang ,  Ian Foltz ,  Gadi Gazit-Bornstein ,  Xiao-Dang Yang ,  David Blakey ,  Sue Cartlidge

IPC分类号： A61K39/395 ,  A61K51/10 ,  C07K16/28 ,  C07K16/30 ,  C12N15/13 ,  C12N15/85 ,  C12N5/06 ,  C12P21/08

CPC分类号： C07K16/2863 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.

摘要翻译： 本文公开了针对抗原PDGFR-α的靶向结合剂及其用途。 更具体地，本发明涉及针对抗原PDGFR-α的完全人单克隆抗体以及这些抗体的用途。 本发明的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所描述的靶向结合剂和抗体可用作诊断和治疗与PDGFR-α的活性和/或过度表达相关的疾病。

公开(公告)号：US20070014720A1

公开(公告)日：2007-01-18

申请号：US11440728

申请日：2006-05-25

申请人： Gadi Gazit-Bornstein ,  Larry Green ,  Xiao-Dong Yang ,  Christophe Queva ,  David Blakey

发明人： Gadi Gazit-Bornstein ,  Larry Green ,  Xiao-Dong Yang ,  Christophe Queva ,  David Blakey

IPC分类号： A61K51/00 ,  A61K39/395 ,  C07H21/04 ,  C12P21/06 ,  C07K16/28

CPC分类号： C07K16/2887 ,  A61K51/1027 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

摘要： Antibodies directed to the antigen CD20 and uses of such antibodies are disclosed herein. In particular, fully human monoclonal antibodies directed to the antigen CD20. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.

摘要翻译： 本文公开了针对抗原CD20的抗体和这种抗体的用途。 特别是针对抗原CD20的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 被披露。 还公开了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

公开(公告)号：US20050006359A1

公开(公告)日：2005-01-13

申请号：US10489327

申请日：2002-09-06

申请人： David Blakey

发明人： David Blakey

IPC分类号： F04B43/04 ,  B01D67/00 ,  B05B1/18 ,  B05B17/06 ,  B23K26/00 ,  B23K26/38 ,  C25F1/00

CPC分类号： B05B1/185 ,  B05B15/40 ,  B05B17/0646 ,  B23K26/384 ,  Y10T29/49432 ,  Y10T29/49433 ,  Y10T29/496

摘要： A method of forming a perforate membrane (1) is disclosed for use in a liquid transport device. The membrane has at least plural nozzles (10) formed therethrough. Each of those nozzles has a throat portion (12) opening at opposite end through opposite surface (2′) of the perforate membrane and a smoothly curved outwardly diverging portion (11) extending from the first end of the throat portion to the first surface (2) of the perforate membrane. Laser energy is applied selectively to the first surface (2) of the membrane in the form of a pulsed, focused beam to form the nozzles (10) and thereafter the first surface (2) of the membrane and the surface of the diverging portion (11) of the nozzles (10) are electro-polished to remove surface imperfections. The electro-polishing is controlled so as to remove material from the surface of the diverging portion (11) of the nozzles to a depth less than the length of the throat portion (12).

摘要翻译： 公开了一种形成穿孔膜（1）的方法，用于液体输送装置。 膜具有穿过其中形成的至少多个喷嘴（10）。 这些喷嘴中的每一个具有通过穿孔膜的相对表面（2'）的相对端开口的喉部（12）和从喉部的第一端延伸到第一表面的平滑弯曲的向外发散部分（11） 2）穿孔膜。 激光能量以脉冲聚焦光束的形式选择性地施加到膜的第一表面（2）以形成喷嘴（10），此后，膜的第一表面（2）和发散部分的表面 11）喷嘴（10）被电抛光以去除表面缺陷。 控制电抛光以便从喷嘴的发散部分（11）的表面移除至小于喉部（12）的长度的深度的深度。

公开(公告)号：US20060246071A1

公开(公告)日：2006-11-02

申请号：US11311939

申请日：2005-12-19

申请人： Larry Green ,  Qing Zhou ,  Bruce Keyt ,  Xiao-Dong Yang ,  Stephen Emery ,  David Blakey

发明人： Larry Green ,  Qing Zhou ,  Bruce Keyt ,  Xiao-Dong Yang ,  Stephen Emery ,  David Blakey

IPC分类号： A61K39/395 ,  C07K16/22

CPC分类号： C07K16/22 ,  A61K39/39558 ,  A61K2039/505 ,  C07K14/515 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92

摘要： Antibodies directed to the antigen Ang-2 and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the antigen Ang-2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.

摘要翻译： 描述针对抗原Ang-2的抗体和这种抗体的用途。 特别是针对抗原Ang-2的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 。 表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。